Petra Schuberth
About Petra Schuberth
Petra Schuberth is the Associate Director of Medical Affairs for Cell Therapy and Hemato-Oncology at Kite Pharma, where she has worked since 2018. She holds a PhD in Tumor Immunology and has extensive experience in oncology and cell therapy, having previously worked at Gilead Sciences and Universitätsspital Zürich.
Work at Kite Pharma
Petra Schuberth serves as the Associate Director of Medical Affairs for Cell Therapy and Hemato-Oncology at Kite Pharma. She has held this position since 2018, contributing to the company's initiatives in Switzerland. In her role, she has budget responsibility and has led pre-launch and launch activities for Yescarta®, a chimeric antigen receptor cell therapy product. Additionally, she acts as a liaison with medical organizations and key opinion leaders in the field of hemato-oncology, facilitating collaboration and communication within the industry.
Education and Expertise
Petra Schuberth has a strong academic background in the life sciences. She obtained her Doctor of Philosophy (PhD) in Tumor Immunology from Universitätsspital Zürich, where she studied from 2008 to 2012. Prior to that, she earned a Bachelor's degree and a Master of Science (MS) in Molecular Biotechnology from Technische Universität München, completing her Bachelor's from 2002 to 2005 and her Master's from 2005 to 2007. This educational foundation supports her expertise in medical affairs and oncology.
Background
Before joining Kite Pharma, Petra Schuberth accumulated extensive experience in the pharmaceutical industry. She worked at Gilead Sciences in various roles, including Medical Project Manager Oncology, Senior Medical Manager Oncology, and Medical Scientist Oncology, from 2016 to 2018. Additionally, she served as a Post-Doc at Universitätsspital Zürich from 2012 to 2014. Her diverse background in medical affairs and oncology positions her as a knowledgeable professional in her field.
Achievements
In her career, Petra Schuberth has played a significant role in establishing a new healthcare reimbursement system in collaboration with health insurances, Swiss hospitals, Swiss DRG, and the Federal Office of Public Health. She also completed an 8-month assignment to establish a Cell Therapy company nationwide in hospitals in Germany. Furthermore, she has served as a global partner for internal medical education at Kite Pharma, enhancing the knowledge base within the organization.